Moximed Secures $91M To Scale Commercialization Of MISHA Knee System
• By Natasha Barrow
Generate a summary of this article
Listen to this article
Moximed aims to accelerate adoption of its MISHA Knee System, De Novo-approved by the US FDA in April 2023, with $91m in Series D funding. Chris Gleason, president and chief executive officer, offers perspective on the company’s innovative technology and commercial growth activities.
• Source: Shutterstock
Moximed will leverage $91m in Series D funding to continue building commercial infrastructure and increase patient access to its pioneering MISHA Knee System.
Following its receipt of US Food and Drug Administration De Novo approval in April 2023, “The MISHA Knee System represents...
Keep up with the top medtech business and regulatory news.
Medtech Insight brings you interviews and analysis, on the go.
When a large medtech company sets up a venture fund, it typically invests in technologies that are adjacent to its pre-existing portfolio. Intuitive Surgical’s approach is different.
This week, Establishment Labs Holdings announced the FDA gave it premarket approval for Motiva breast implant, Cologuard lands FDA approval for Cologuard Plus and GE HealthCare gets FDA nod for a new imaging agent. The FDA announces another expansion for TAP into ophthalmology and radiology. The AAMI and CTA will join forces to develop standards for AI and ML-enabled health care products.
Spain has one of the highest incarceration rates in Europe, with 160 individuals imprisoned per 100,000 residents. In 2020, 43,494 people were incarcerated in facilities not managed by regional health authorities — essentially all regions except Catalonia, the Basque Country, and Navarra.
The medtech companies navigate tariffs through a mix of proactive manufacturing moves, financial planning and global supply chain adjustments. Medtech Insight combined comments from executives made during their first-quarter earning calls to get an industry pulse check on how the surge of tariffs im
This week, Establishment Labs Holdings announced the FDA gave it premarket approval for Motiva breast implant, Cologuard lands FDA approval for Cologuard Plus and GE HealthCare gets FDA nod for a new imaging agent. The FDA announces another expansion for TAP into ophthalmology and radiology. The AAMI and CTA will join forces to develop standards for AI and ML-enabled health care products.